{"schema_version":"secwatch.filing_event.v1","accession":"0001877322-22-000019","form_type":"8-K","ticker":"ESAB","cik":"0001877322","company_name":"ESAB Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.878983+00:00","generated_at":"2026-06-22T09:55:42.121272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ESAB Q3 beats: core adj. EPS $0.92, raises FY core adj. EPS guidance to $4.00-$4.10","bullets":["GAAP EPS $0.88, core adjusted diluted EPS $0.92; net income $53M from continuing ops.","Revenue $620M (+2% reported); core organic growth 10% excluding Russia and currency.","Core adjusted EBITDA $96M, up 5% YoY; reaffirms 2022 core organic growth 11-14%.","Raises FY core adjusted EPS guidance to $4.00-$4.10 from $3.85-$4.05; core EBITDA narrowed to $405-415M.","Completed Ohio Medical acquisition; gas control platform now >$400M sales with >40% gross margins."],"urls":{"canonical":"https://secwatch.observer/filing/0001877322-22-000019","json":"https://secwatch.observer/filing/0001877322-22-000019.json","markdown":"https://secwatch.observer/filing/0001877322-22-000019.md","text":"https://secwatch.observer/filing/0001877322-22-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877322/000187732222000019/0001877322-22-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877322/000187732222000019/esab-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:55:42.121272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd9080693221c3120c6bfdd25f62fe2683daba53","claim":"ESAB Corp reported third quarter of 2022 results: revenue $620 million, net income $53 million, EPS $0.88 diluted per share. Guidance reaffirmed.","evidence_excerpt":"The Company reported third quarter sales of $620 million, an increase of 2% on a reported basis, and core (excluding Russia) sales of $577 million, or 10% higher core organic growth before currency translation impacts. ESAB also reported third quarter GAAP net income from continuing operations attributable to ESAB of $53 million , $0.88 diluted per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1877322/000187732222000019/0001877322-22-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Revenue","value":"$620 million"},{"label":"Net income","value":"$53 million"},{"label":"EPS","value":"$0.88 diluted per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}